Aptitude is hiring! See current openings.
Aptitude demonstrated the in vivo efficacy of two aptamer therapeutic programs
Aptitude has received 5 million dollars in non-dilutive funding
Aptitude started collaboration with a global leader in clinical diagnostics
Imagine a synthetic antibody that:
binds with high affinity and specificity to targets such as small organics, peptides, proteins, cells, and tissues
discriminates targets which differ in structure by only a single functional group
is utilized as high sensitivity targeting reagents for research, diagnostics, and therapeutics
Imagine a company who can turn that dream into reality.
Welcome to the reality of Aptitude.
Find out who is behind the Aptitude technology